Cargando…

Type I Interferon: Potential Therapeutic Target for Psoriasis?

BACKGROUND: Psoriasis is an immune-mediated disease characterized by aberrant epidermal differentiation, surface scale formation, and marked cutaneous inflammation. To better understand the pathogenesis of this disease and identify potential mediators, we used whole genome array analysis to profile...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Yihong, Richman, Laura, Morehouse, Chris, de los Reyes, Melissa, Higgs, Brandon W., Boutrin, Anmarie, White, Barbara, Coyle, Anthony, Krueger, James, Kiener, Peter A., Jallal, Bahija
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2481274/ https://www.ncbi.nlm.nih.gov/pubmed/18648529 http://dx.doi.org/10.1371/journal.pone.0002737

Ejemplares similares

Correction: Type I Interferon: Potential Therapeutic Target for Psoriasis?
por: Yao, Yihong, et al.
Publicado: (2009)

Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus
por: Yao, Yihong, et al.
Publicado: (2009)

Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus
por: Yao, Yihong, et al.
Publicado: (2010)

Altered Expression of Insulin Receptor Isoforms in Breast Cancer
por: Huang, Jiaqi, et al.
Publicado: (2011)

Genomic signatures characterize leukocyte infiltration in myositis muscles
por: Zhu, Wei, et al.
Publicado: (2012)

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
por: Higgs, Brandon W, et al.
Publicado: (2014)

Developing innovative targeted therapies for China
por: Jallal, Bahija
Publicado: (2012)

microRNA-mediated regulation of innate immune response in rheumatic diseases
por: Luo, Xiaobing, et al.
Publicado: (2013)

Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis
por: Guo, Xiang, et al.
Publicado: (2014)

Interferon and Biologic Signatures in Dermatomyositis Skin: Specificity and Heterogeneity across Diseases
por: Wong, David, et al.
Publicado: (2012)

Psoriasis and Hepatitis C: Improvement with Interferon
por: Habte-Gabr, Eyassu, et al.
Publicado: (2011)

Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus
por: Riggs, Jeffrey M, et al.
Publicado: (2018)

Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinoma
por: Jiang, Liyan, et al.
Publicado: (2014)

Interferon Kappa Is Up-Regulated in Psoriasis and It Up-Regulates Psoriasis-Associated Cytokines in vivo
por: Li, Yuanyuan, et al.
Publicado: (2019)

Mi conejo /
por: Barrie Anmarie
Publicado: (2000)

Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer
por: Jiang, Liyan, et al.
Publicado: (2016)

Role of interferon regulatory factor-mediated signaling in psoriasis
por: Wang, Wen-Ming, et al.
Publicado: (2021)

Extensive psoriasis induced by pegylated interferon: a case report
por: Citro, Vincenzo, et al.
Publicado: (2007)

The Role of Plasmacytoid Dendritic Cells and Interferon-Alpha in the Immunopathogenesis of Psoriasis
por: Denadai, Rafael
Publicado: (2013)

Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis
por: Steele, Keith E., et al.
Publicado: (2018)

Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis
por: Sarma, Nilendu
Publicado: (2017)

BubbleTree: an intuitive visualization to elucidate tumoral aneuploidy and clonality using next generation sequencing data
por: Zhu, Wei, et al.
Publicado: (2016)

Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study
por: Petri, Michelle, et al.
Publicado: (2013)

Plasmacytoid predendritic cells initiate psoriasis through interferon-α production
por: Nestle, Frank O., et al.
Publicado: (2005)

High-throughput RNA sequencing reveals distinct gene signatures in active IgG4-related disease
por: Higgs, Brandon W., et al.
Publicado: (2017)

What Racism Has to Do with It: Understanding and Reducing Sexually Transmitted Diseases in Youth of Color
por: Boutrin, Marie-Claire, et al.
Publicado: (2021)

An online database for brain disease research
por: Higgs, Brandon W, et al.
Publicado: (2006)

An autoimmune “attack” on melanocytes triggers psoriasis and cellular hyperplasia
por: Krueger, James G.
Publicado: (2015)

Interferons and their Therapeutic Applications
por: Strannegård, Örjan
Publicado: (1999)

Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon
por: Mylonas, Alessio, et al.
Publicado: (2018)

Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe Psoriasis
por: Suárez-Fariñas, Mayte, et al.
Publicado: (2012)

Molecular and Cellular Profiling of Scalp Psoriasis Reveals Differences and Similarities Compared to Skin Psoriasis
por: Ruano, Juan, et al.
Publicado: (2016)

HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma
por: Xue, Feng, et al.
Publicado: (2015)

Therapeutic drug monitoring of biologics in psoriasis
por: Liau, MeiQi May, et al.
Publicado: (2019)

Therapeutic challenges in managing pediatric psoriasis
por: Goenaga-Vázquez, Yamila, et al.
Publicado: (2020)

Treatment Options and Goals for Patients with Generalized Pustular Psoriasis
por: Krueger, James, et al.
Publicado: (2022)

Type1 Interferons Potential Initiating Factors Linking Skin Wounds With Psoriasis Pathogenesis
por: Zhang, Ling-juan
Publicado: (2019)

TST conversions and systemic interferon-gamma increase after methotrexate introduction in psoriasis patients
por: de Medeiros, Vanessa Lucília Silveira, et al.
Publicado: (2020)

Enhanced serum interferon-lambda 1 interleukin-29 levels in patients with psoriasis vulgaris()()
por: Fu, Li-xin, et al.
Publicado: (2021)

Suppression of IL‐12/IL‐23 p40 subunit in the skin and blood of psoriasis patients by Tofacitinib is dependent on active interferon‐γ signaling in dendritic cells: Implications for the treatment of psoriasis and interferon‐driven diseases
por: Vincken, Nanette L. A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mekp62q2tc1sf7naccu9b8p1lf